Advances and Novel Treatment Options in Metastatic Melanoma

doi:10.3390/books978-3-0365-3303-2

Format

Hardback

License and Copyright

Keywords

melanoma; invasion; WNT5A; MARCKS; phosphorylation; MANS peptide; melanoma; nanoparticles; cell therapy; tumor microenvironment; melanoma; sex/gender; sex-hormones; immunity; microRNAs; immunotherapy; BRAF-mutant melanoma; BRAF inhibitor; mechanism of action; melanoma; targeted therapy; tumour microenvironment; plasmacytoid dendritic cells; melanoma; lactate dehydrogenase; TLR; interferon; CXCL10; TPC2; HIPPO; melanoma; SOCE; metastasis; melanoma; essential oils; angiogenesis; apoptosis; metastasis; uveal melanoma (UM); metastatic uveal melanoma (mUM); prognostication; adjuvant therapy; metastatic therapy; metastatic dormancy; liver-directed-therapies; immunotherapy; targeted-therapy; combined therapy; melanoma; protein tyrosine phosphatase; PTPs inhibitors; melanoma immune infiltrate; BRAF inhibitors; melanoma; metastasis; microenvironment; resistance; therapy; melanoma; targeted therapy; immunotherapy; tumor microenvironment; therapeutic resistance; nanoparticles; exosomes; extracellular vesicles; melanoma; therapy; diagnosis; prognosis; ctDNA; melanoma; liquid biopsy; prognosis; prediction; patient stratification; melanoma; BRAF; BRAF inhibitor; arthralgia; rheumatoid arthritis; carbonic anhydrase; hedgehog; cyclopamine; small molecules; acetazolamide; motility; metalloproteinases; FAK; cancer; mucosal melanoma; nivolumab; pembrolizumab; ipilimumab; radiotherapy; cholinergic system; acetylcholine; muscarinic receptors; nicotinic receptors; melanoma; cancer; melanoma metastasis; ShcD adaptor protein; amoeboid motility; Rac1; DOCK4; melanoma PDX; melanoma; target therapy; cancer stem cells; slow cycling phenotype; drug resistance; OXPHOS; lipid metabolism; melanoma; cancer associated fibroblast; tumor microenvironment; melanomagenesis; biomarkers; melanoma; checkpoint inhibitor; PD-1; target therapy; melanoma markers; cytokines; machine learning; Support Vector Machine; principal component analysis; BCL2L10; STAT3; melanoma; cytotoxicity; survival; ABT-737; Bcl-2 family; ML258; melanoma; HuR; MITF; metastases; siRNA; targeted therapy; nanoparticles; n/a

Reprint

Download Flyer

Advances and Novel Treatment Options in Metastatic Melanoma

Edited by

February 2022

528 pages

ISBN978-3-0365-3304-9 (Hardback)
ISBN978-3-0365-3303-2 (PDF)

https://doi.org/10.3390/books978-3-0365-3303-2

Free Download (PDF)

This is a Reprint of the Special Issue Advances and Novel Treatment Options in Metastatic Melanoma that was published in

Biology & Life Sciences

Medicine & Pharmacology

Summary

The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.

Related Books

March 2022

Advances and Novel Treatment Options in Metastatic Melanoma

Related Books

New Advances in Melanoma

Advanced Molecular Solutions for Cancer Therapy

Novel Treatment Strategies for Glioblastoma

Prevention, Diagnosis and Treatment of Skin Cancer

Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies